Safety and Efficacy Study of NGGT002 in cPKU Adult Subjects

Launched by NGGT (SUZHOU) BIOTECHNOLOGY CO., LTD. · Nov 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called NGGT002 for adults with a condition known as classic Phenylketonuria (PKU). PKU is a genetic disorder that affects how the body processes a protein called phenylalanine, which can build up in the blood and cause serious health issues if not managed. The study aims to see if NGGT002, which contains a healthy copy of the PAH gene that is missing or not working properly in people with PKU, is safe and effective. Participants will receive a single dose of NGGT002 and will be monitored for up to five years to assess how well it works and to check for any side effects.

To join the study, participants should be between 18 and 55 years old and have specific genetic markers related to PKU. They need to have high levels of phenylalanine in their blood and be willing to manage their diet carefully. The trial is open to all genders, but individuals with certain health conditions or who are well-managed on existing PKU treatments may not be eligible. If someone qualifies, they can expect regular follow-ups and support throughout the five-year study period, helping researchers learn more about this potential new treatment for PKU.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Voluntarily participating in the study and signing the informed consent form;
• • 2. Gender is not limited; patients must carry biallelic pathogenic or likely pathogenic variants in the PAH gene;
• • 3. Adult patients aged 18 to 55 years;
• • 4. In the past 24 months, at least two blood Phe concentrations have been ≥600 μmol/L (10 mg/dL), with at least one of these measurements taken within 6 months prior to the screening period;
• • 5. Willing and able to manage their diet;
• • 6. According to the investigator's opinion, willing and able to comply with the study procedures and requirements;
• • 7. Women of childbearing potential must have a negative serum HCG test within 7 days before dosing. Participants must agree to use highly effective contraceptive measures for at least one year after receiving NGGT002.
• Exclusion Criteria:
• • 1. Presence of anti-AAV8 neutralizing antibodies（≥1:5）
• • 2. Subjects whose disease is well-controlled with existing therapies, such as those currently receiving medications like Sapropterin Dihydrochloride tablets, Pegvaliase-pqpz, etc.;
• 3. Before dosing, the patient's hematological laboratory tests exceed any of the following limits:
• • Alanine Transaminase (ALT) \> 1.5×ULN and/or Aspartate Aminotransferase (AST) \> 1.5×ULN
• • Alkaline Phosphatase (ALP) \> 1.5×ULN
• • Total Bilirubin (TBil) \> 1.5×ULN, Direct Bilirubin \> 1.5×ULN
• • International Normalized Ratio (INR) \> 1.5
• • Serum Creatinine (Scr) \> 1.5×ULN
• • Hematological values outside the normal range (Hemoglobin: \<110 g/L for males, \<100 g/L for females, White Blood Cells \<3.0×10\^9/L, Neutrophils \<1.5×10\^9/L, Platelets \<100×10\^9/L)
• • Glycated Hemoglobin (HbA1c) \> 6% or Fasting Blood Glucose \> 6.1 mmol/L
• • 4. At screening, clinically significant abnormal vital signs, physical examination, laboratory test results, or other relevant findings that, in the investigator's opinion, make the subject unsuitable for inclusion;
• • 5. In the investigator's assessment, the subject has contraindications to corticosteroid use or conditions that could lead to a worsening of the condition;
• • 6. Hepatitis A virus infection, active or occult hepatitis B virus infection, active hepatitis C virus infection, positive for Human Immunodeficiency Virus (HIV) antibodies, positive syphilis test, active or latent tuberculosis (TB) infection;
• • 7. A significant history of liver disease, such as steatosis, fibrosis, non-alcoholic steatohepatitis, and cirrhosis, biliary diseases, within 6 months prior to signing the informed consent form, except for Gilbert's syndrome;
• • 8. History of malignant tumors;
• • 9. Imaging (liver ultrasound) evidence of severe liver diseases such as hepatic fibrosis or cirrhosis;
• • 10. In the investigator's assessment, the subject has a history of serious cardiovascular, respiratory, gastrointestinal, endocrine, renal, hematological, neurological, psychiatric, or other systemic diseases before screening;
• • 11. History of allergy to human serum albumin;
• • 12. Subjects with a history of substance abuse (e.g., alcohol, heroin, amphetamines, etc.);
• • 13. Subjects who have received gene therapy at any time in the past.
• • 14. Subjects who have participated in other non-gene therapy drug clinical trials and received the investigational drug within 3 months (or 5 half-lives of the other investigational drug) prior to screening;
• • 15. Subjects with elevated Alpha-fetoprotein (AFP);
• • 16. Other conditions that, in the investigator's opinion, make the subject unsuitable for inclusion, such as severe comorbidities associated with PKU (e.g., renal insufficiency or renal failure, osteoporosis, anemia, gastroesophageal reflux or peptic ulcer, major depressive disorder, epilepsy, etc.);
• • 17. Subjects weighing more than 100 kg;
• • 18. Subjects whose daily diet includes excessive natural protein intake (\>2 g/kg/day).